QuidelOrtho Corporation (QDEL)

Over the past six months, QuidelOrtho's stock has experienced fluctuations. The stock gained 22.9% as of January 15, 2026, outperforming its industry. On October 6, 2025, the stock was down 21.9% due to concerns about declining respiratory revenue. On November 11, 2025, the stock was up 5.1% linked to a price surge and insider buying activity. In early February 2026, the stock price was around $28.69, with a 52-week range between $19.50 and $47.61. Q3 2025 results showed revenue exceeding expectations, though sales fell year-on-year. A positive outlook for the respiratory season and a price target raise contributed to a stock increase in January 2026. Insider transactions show a mix of buys and sells.

QuidelOrtho's business experiences demand seasonality, particularly concerning its respiratory products. Demand is typically higher during the fall and winter cold and flu seasons. The decline in COVID-19 revenue and the sensitivity of flu volumes to seasonal dynamics have impacted the company's financial results.

QuidelOrtho Corp. is a healthcare company specializing in rapid diagnostic testing solutions. It operates in the medical devices and diagnostic equipment industry, with core business areas including immunoassay and molecular testing, clinical chemistry, and transfusion medicine. The company's product portfolio includes solutions for various diseases and health areas, utilizing platforms like Sofia, QuickVue, Lyra, Solana, Savanna, Vitros Systems, and Ortho Vision Swift.

QuidelOrtho Corp. has a significant global presence with operations in North America, EMEA, and China. North America accounts for the majority of the company's revenue. It has manufacturing facilities in the United States and the United Kingdom, supported by a global network of sales centers, administrative offices, and warehouses. Its products are marketed through distributors and a direct sales force to a broad customer base across more than 130 countries.

QuidelOrtho has a reputation as a world leader in in vitro diagnostics, built on a history of innovation. It has been a pioneer in women's health diagnostics, rapid antigen tests for Influenza A and B, and the first FDA emergency use authorized rapid antigen test for COVID-19. Financial challenges, including revenue decline and negative earnings per share, can indirectly influence public perception and investor confidence. The company is actively working on restructuring and cost-saving initiatives.

QuidelOrtho Corporation is predominantly owned by institutional investors, who collectively held approximately 112.15% of the company's shares as of March 2025. Major institutional owners include T. Rowe Price Investment Management, Inc., BlackRock, Inc., and Vanguard Group Inc. The largest individual shareholder is Jack W. Schuler, owning 12.63% of the company's shares. Insiders collectively owned 0.63% as of March 2025.